The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised Tuesday to examine lowering their prices in the United States, after coming under pressure from Congress.
This article was originally published on MedicalXpress.com